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ABSTRACT 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly. It is 
fundamentally necessary to discovery and establish reliable and accurate biomarkers that 
are capable of predicting, diagnosing and monitoring disease progression. Here we report 
on a set of glycoproteins and endogenous peptides identified and compared in 
cerebrospinal fluid (CSF) from cognitively healthy individuals and patients with mild 
cognitive impairment or AD via mass spectrometry (MS)-based strategies. Using an 
optimized sub-microgram peptide separation with molecular weight cut-off filtration and 
an in house-constructed database, 645 peptides were identified. Glycoproteins were 
enriched by lectin affinity chromatography, resulting in 795 identified peptides. The 
discovery and alterations of ProSAAS-derived peptides and transthyretin are described 
and their roles in AD are discussed.   
 
 
INTRODUCTION 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly 
population and the 6th leading cause of death in the United States. More than 36.5 
million people were estimated to suffer from dementia in 2010, and there are 7.7 million 
new cases each year. Due to the aging baby boom generation, it is predicted that the 
number of people with Alzheimer's disease age 65 and older may triple by 2050, costing 
an estimated $1.2 trillion.1 AD is characterized by progressive accumulation of 
extracellular β-amyloid (Aβ) peptides and intracellular neurofibrillary tangles of protein 
tau, in addition to synaptic and neuronal loss in the brain.2 Currently, the diagnosis of AD 
is mainly based on the history of a patient or an objective cognitive assessment and the 
exclusion of dementia due to other causes such as Lewy body dementia, vascular 
dementia, frontotemporal dementia, Creutzfeldt-Jakob disease (CJD), etc.3 Three AD 
biomarkers: Aβ 1-42, total tau (t-tau) and phosphorylated tau (p-tau) in the cerebrospinal 
fluid (CSF) have been used to support a clinical diagnosis.4, 5, 6, 7 These biomarkers may 
increase the certainty of AD pathophysiological process in patients who have already met 
the critical clinical criteria for probable AD dementia. However, additional markers are 
needed; one limitation of the current CSF tau and A markers is that they do not change 
with clinical disease progression but are fully altered already in the mild cognitive 
impairment stage of the disease (ref: Blennow K et al., Nat Rev Neurol 2010). Moreover, 
they do not reflect pathophysiological processes, other than plaque and tangle pathology, 
that may be of importance. Specifically, the recently reported failure of a phase 3 clinical 
trial of humanized monoclonal antibody of soluble forms of amyloid8, 9 necessitates the 
discovery and establishment of other biomarkers and targets for disease prevention and/or 
treatment.      
 
CSF bathes the brain and spinal cord which makes it a valuable biological fluid for 
biomarker studies of neurodegenerative diseases.10 Although CSF sampling may be 
considered an invasive, the procedure is well tolerated by patients and the only 
complication, provided that standard contraindications are considered, is post-lumbar 
puncture headache, which is a rare event in the elderly (Blennow K et al., Nature Rev 
Neurol 2010). Approximately 70-80% of the CSF is generated in the choroid plexus as a 
plasma filtrate. The remaining 20-30% is derived from the brain interstitial fluid and 
there are no barriers between the CSF and the brain extracellular matrix. The total CSF 
volume is around 150 mL; the CSF production and clearance rates are 20 mL per hour 
and in a regular lumbar puncture 10-20 mL is collected, which is then rapidly 
replenished.13+Blennow 2010 Nat Rev Neurol Despite the differences between CSF and 
plasma the proteome of both share the vast majority of abundant protein identifications, 
although it is estimated that around 20% of the CSF proteome are produced by brain 
itself.11, 12 CSF is reabsorbed into the blood four times per day and due to the constant 
turnover the dynamic changes of CSF composition is able to reflect the disease status of 
the central nervous system (CNS). In a clinical setting, the lumbar puncture is a routine 
procedure for the diagnosis of multiple sclerosis, Guillain-Barré syndrome and CJD etc. 
Previous large scale proteomic studies have greatly filled in the gap of our knowledge 
about CSF protein composition by two dimensional gel,14, 15, 16, 17 chromatography and 
mass spectrometry.18, 19, 20, 21, 22   
  
Glycosylation is one of the most complicated but common forms of post-translational 
modifications in proteins. It modulates cell-molecule, cell-matrix and cell-cell 
interactions and facilitates the assembly and development of complex organisms. The 
major functions of a glycan can be characterized into two categories: (1) structural and 
modular functions; and (2) recognition of glycans by other molecules.23 There are two 
major forms of protein glycosylation: glycans linked to an asparagine (N-glycans) and 
glycans linked to a serine/threonine (O-glycans). N-glycosylation occurs in the 
endoplasmic reticulum (ER) while O-glycosylation is more dynamic occurring in nuclear 
and cytoplasmic proteins. Lectin affinity chromatography is a useful and practical 
separation technique in glycoproteomics. It is characterized by selectively binding a 
specific carbohydrate motif. Among them, concanavalin-A (ConA) and wheat germ 
agglutinin (WGA) are most commonly used. Specifically, ConA has higher affinity for 
N-linked glycoproteins with high-mannose and terminal glucose carbohydrates while 
WGA has a higher affinity for terminal acetylglucosamine and sialic acid with O-linked 
glycosylation motif. In addition, ConA has a special binding site for excessively 
hydrophobic proteins while WGA is able to bind both hydrophobic and hydrophilic 
proteins.24 Their functional properties are useful to utilize as a combination of both ConA 
and WGA which can obtain effective glycoprotein enrichment.  Previous studies indicate 
that the global protein glycosylation pattern is altered in AD.25, 26, 24 Recently, the 
potential precursor of AD, mild cognitive impairment (MCI), has drawn increased 
attention since treatments could potentially be initiated before the damage of the 
neurodegenerative process becomes too extensive.27, 28 One can investigate patients with 
cognitive impairment that is worse than age-matched healthy individuals but not severe 
enough to fulfill the criteria for suspected AD. People with MCI display similar 
pathophysiologic symptoms as those with AD and have a 10%-15% relative risk of 
progressing to AD dementia annually.29, 30  Here we report a comparative glycoproteomic 
and peptidomic discovery study using CSF from healthy (control), MCI and AD 
individuals via mass spectrometry (MS). This study demonstrates the usefulness of 
glycoprotein enrichment in biomarker discovery which facilitates the isolation, 
identification and relative quantification of lectin affinity enriched glycoproteins from 
CSF samples via multidimensional separation and high resolution accurate mass tandem 
mass spectrometry.  
 
MATERIALS AND METHODS 
 Participants  
Twelve enrollees in the Wisconsin Alzheimer’s Disease Research Center (ADRC) 
participated in this study. This research was conducted in March 5, 2010 to February 13, 
2013. The samples comprised of four cognitively normal individuals who enrolled in the 
Wisconsin ARDC at late middle age without family history of AD and eight patients with 
cognitive impairment. The cognitively impairment group consisted of four people with 
amnestic MCI and four people with mild AD. All AD and MCI participants were 
diagnosed via applicable clinical criteria characterized by standardized, consensus, 
multidisciplinary consensus conferences,31, 3 while cognitive normalcy was determined 
based on intact cognitive performance by a comprehensive battery of neuropsychological 
tests, lack of functional impairment, and absence of neurological or psychiatric 
conditions that might impair cognition.32, 33 Women comprised seven out of a total of 
twelve participants and the mean (SD) age of the total sample was 75.24 (±3.37) years. 
Cognitive reserve (CR) was indexed by years of education. Individuals with fewer than 
16 years of education were considered as having low CR (n=2), while those with at least 
16 years of education were considered as having high CR (n=10).34 The University of 
Wisconsin Institutional Review Board approved all study procedures. Each enrollee 
provided a signed informed consent form before participation.   
 
CSF Collection  
A lumbar puncture for CSF sample collection was performed in the morning after a 12-
hour fast. A Sprotte 24-gauge or 25-gauge spinal needle was inserted at L3/4 or L4/5 
following proper local anesthesia. Each CSF sample was collected via syringes into 
polypropylene sample collection tubes. The total CSF sample (approximately 22 mL) was 
gently mixed to avoid gradient effects, centrifuged at 2000g for ten minutes and the 
supernatant was collected in 0.5 mL aliquots in polypropylene tubes, frozen and stored at 
-80ºC. The samples were immunoassayed for Aβ1-42, t-tau and p-tau by enzyme-linked 
immunosorbent assays (INNOTEST; Fujirebio) by board-certified technicians who were 
blind to clinical data and used protocols accredited by the Swedish Board for 
Accreditation and Conformity Assessment as described in a previous report.35 Table 1 
represents the demographic characteristics of the study participants. The mean age of all 
individuals was 75 with a SD of ±3.4, ranging from 70.3 to 82.5.  The mean number of 
years of education was 16.4 with an SD of 2.5.    
 
Materials 
Iodoacetamide (IAA), N-acetyl-D-glucosamine, methyl-R-D-mannopyranoside, methyl-
R-D-glucopyranoside, manganese chloride tetrahydrate and protease inhibitor cocktail 
were purchased from Sigma-Aldrich (St. Louis, MO). Ammonium bicarbonate, urea, 
formic acid (FA), Tris hydrochloride, acetonitrile, methanol, optima LC/MS grade water, 
sodium chloride (99.5%), calcium chloride, and sodium acetate were obtained from 
Thermo Fisher Scientific (Pittsburgh, PA). Agarose bound Concanavalin A (Con A, 6 mg 
lectin/mL gel) and Wheat Germ Agglutinin (WGA, 7 mg lectin/mL gel) were obtained 
from Vector Laboratories (Burlingame, CA). Sequencing grade modified trypsin and 
dithiothreitol (DTT) were from Promega (Madison, WI). 660 nm protein assay kit was 
purchased from Pierce (Rockford, IL) and microplate reader was purchased from BioTek 
Instrument (Winooski, VT). Amicon Ultra 0.5 mL 10,000 molecular weight cut-off 
(MWCO) membrane-based centrifugal filters and C18 ZipTips were purchased from 
Millipore (Billerica, MA). 100 μL Omix Tips packed with C18 reversed-phase resin were 
obtained from Agilent (Palo Alto, CA). 
 
Peptide separation   
Two aliquots of CSF samples (total 1 mL) of each participant were used for this study. 
Protease inhibitor cocktail was added to the CSF by the recommended ratio immediately 
before use. Endogenous peptide separations were performed using Amicon Ultra 0.5 mL 
10,000 MWCO centrifugal filters. Before the MWCO separation, three washing steps 
were performed to remove the contaminants from the filter and achieve optimal peptide 
coverage. The three washes were 500 μL water: methanol, 500 μL of water, and 400 µL 
70:30 aqueous 1 M sodium chloride:methanol. This method yielded a better peptide 
coverage after separated from a complex protein mixture and was reported by our 
previous study.36 The MWCO filter was subjected to centrifugation at 14,000 g for 5 min 
at 4ºC via an Eppendorf 5415 D microcentrifuge (Brinkmann Instruments Inc., Westbury, 
NY). The flow-through was then concentrated by a Savant SC 110 SpeedVac 
concentrator (Thermo Electron Corporation, West Palm Beach, FL) and resuspended in 
20 μL 0.1% formic acid. The resulting sample was desalted by C18 ZipTips by the 
manufacturer’s protocol. Specifically, the ZipTips were washed with 100% ACN and 
then pre-equilibrated with 0.1% formic acid in water for three times respectively. Next, 
the endogenous peptides were loaded onto the C18 ZipTips repeatedly and gently. The 
loaded peptides were desalted using 0.1% formic acid in water three times and then 
eluted in 20 μL of 50% ACN in 0.1% formic acid. Subsequently, the solution was dried 
down and resuspended in 10 μL 0.1% formic acid in water and subjected to LC MS/MS 
analysis.  
 
Lectin Affinity Chromatography 
Lectin affinity columns were prepared in house by adding 75 μL WGA and 150 μL ConA 
slurry both bound to agarose beads into an empty Spin Columns-Screw Cap (Pierce, 
Rockford, IL). The columns were washed two times to remove contaminants with lectin 
affinity chromatography (LAC) binding buffer (0.15 M NaCl, 0.02 M Tris-HCl, 1 mM 
CaCl2, pH=7.4). Each time the columns were centrifuged at 400 g for 30 seconds with 
the bottom plug removed. Subsequently, 500 μL CSF was loaded into the lectin affinity 
column with the bottom plug placed back. After incubating with continuous mixing at 
room temperature for two hours, the sample was centrifuged at 400 g for 30 seconds and 
the unbound flow-through fraction was discarded. The lectin beads were washed with 
300 μL LAC binding buffer twice, centrifuged, and flow-through discarded. The lectin 
beads with captured glycoproteins were eluted after vortexing for 10 minutes with 300 μL 
LAC eluting buffer (0.075 M NaCl, 0.01 M Tris-HCl, 0.2 M alphamethyl mannoside, 0.2 
M alpha-methyl glucoside, and 0.5 M acetyl-D-glucosamine) and the elution protocol 
was performed twice and combined for each participant. The protein concentration was 
determined by 660 nm protein assay and the final protein amount was normalized for all 
participant samples.  
    
Protein digestion       
Each sample consisted of 20 μg of protein and was denatured with 8 M urea in 50 mM 
ammonium bicarbonate buffer and reduced by DTT (final concentration as 20 mM) via 
incubation at 37 °C for 1 h. After incubation, the reduced sample was alkylated by IAA 
and allowed to react in the dark for 15 min, making final concentration of IAA as 60 mM. 
Afterwards, DTT was added to quench IAA and incubated for 10 min. The sample was 
diluted to 1 M urea by 50 mM ammonium bicarbonate (pH=8.5) followed by addition of 
trypsin (trypsin: protein= 1: 40). The digestion was incubated for 18 h at 37°C and 
subsequently quenched by 2.5 μL 10% formic acid. The solid phase extraction of the 
tryptic peptides were performed by Varian 100 μL C18 Omix Tips (Palo Alto, CA) by 
similar steps as described above. The peptides were sequentially eluted with 50% ACN in 
0.1% formic acid, dried by SpeedVac and reconstituted with 20 μL 0.1% formic acid.  
 
LC – ESI Orbitrap mass spectrometry data acquisitions 
Online reversed-phase liquid chromatography separation of the tryptic peptides was 
performed on a nanoAcquity UPLC (Waters Corp., Milford, MA) and infused into a Q 
Exactive quadrupole orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, 
CA). The chromatographic separation was carried out via mobile phase A that consisted 
of 0.1% formic acid in water and mobile phase B consisting of 0.1% formic acid in ACN. 
One μL of tryptic or endogenous peptides was loaded onto a 2 cm, 150 μm i.d. PLRP-S 
dp 5 μm, pore size 1000 Å, trap column at a flow rate of 5 μL/min for 5 minutes at 95% A 
and 5% B, and subsequently separated by a Waters BEH 130 Å C18 reversed-phase 
capillary column (150 mm × 75 μm, 1.7 μm). Emitter tips were pulled from capillary 
tubing 75 μm I.D. (Polymicro Technologies, Phoenix, AZ) using a model P-2000 laser 
puller (Sutter Instrument Co., Novato, CA). The LC gradient was 5-30% B over 120 
minutes at a flow rate of 350 nL/min. Ions were generated under positive electrospray 
ionization (ESI) at a capillary voltage of 2.8 KV; 275°C capillary temperature; 30% 
collision energy via high energy collision dissociation (HCD). MS1 scans were acquired 
over 200–2000 m/z at 70 k resolution followed by data dependent selection of the top 10 
most abundant precursor ions with an isolation window of 2.0 m/z.  HCD fragmentation 
was then performed and analyzed at a resolution of 17,500. Other parameters include: 
automatic gain control 1e5; maximum ion injection time, 100 ms; dynamic exclusion 
enabled with unassigned, +1 and greater than +8 charges ignored for MS/MS selection. 
Each sample was injected three times to acquire technical triplicates.  
 
Data analysis  
Endogenous peptide discovery was performed via Peaks Studio 7 software 
(Bioinformatics Solutions Inc., Waterloo, ON, Canada). All raw LC-MS/MS data were 
processed by Peaks software for spectral interpretation. The database was in-house 
constructed based on Uniprot’s reference database of Homo sapiens (release 06_2014) by 
predicting neuropeptides sequence based on in silico peptide cleavage principles.37 There 
were 16690 entries in total. Data Refinement was applied as default to correct the 
precursor mass and charge states. For De Novo and Peaks Search the parameters were: 
non-enzyme; MS 1 and MS/MS mass tolerance as 10 ppm and 0.1 Da respectively; 
amidation (C-terminal), acetylation (N-terminal), oxidation, pyroglutamination of 
glutamic acid and glutamine as variable PTMs; monoisotopic mass values. Estimation of 
false positive identification rate was determined by searching all sepctra against a decoy 
database and with a false discovery rate (FDR) set at ≤1%, and only peptides with -10 
logP score  15 were considered as confident identifications.   
  
Tryptic peptide identification was carried out via Proteome Discoverer 1.4 (Thermo 
Scientific). A FASTA file was downloaded from Uniprot’s reference database of Homo 
sapiens (release 06_2014). Other parameters include: allowed missed cleavage, 1; 
enzyme, trypsin; fixed modification, carbamidomethylation of cysteine (+57.0215 Da); 
variable modification, oxidation of methionine (+15.9949 Da); peptide mass tolerance, 10 
ppm; fragment mass tolerance, 0.1 Da. q value was set to achieve 1% false discovery rate 
(FDR) via the Percolator node to verify the identified peptides, and the results were 
filtered by high confidence peptide identification. Only protein identifications that 
appeared in at least two technical replicates were considered. Label free quantification 
(LFQ) was conducted to compare control, MCI and AD glycoproteins. Protein 
concentration was estimated by the sum of normalized peak areas of its tryptic peptides. 
Area under curve of acquired data was automatically calculated by Proteome Discoverer 
1.4 by an event detection node that was applied at a setting of 4 ppm along with the 
precursor ion peak detector node to extract ion chromatograms. Only unique peptides to 
one assigned protein were calculated and summed to achieve the cumulative peak area. 
One way ANOVA analysis was applied to detect the significant protein differential 
expression. Online software was applied and data was manually input into Statistica. 
Protein peak area with significant changes in statistical analysis was subjected to post-hoc 
comparisons among means via Tukey’s HSD test. P < 0.05 was considered to be 
statistically significant. Only proteins that were identified in three out of four individuals’ 
CSF in each group were further analyzed by one way ANOVA. 
 
 
RESULTS AND DISCUSSION 
 
Endogenous Peptide Discovery  
Figure 1 demonstrates the schematic illustration of the experimental design which 
enabled detection and analysis of large proteins and endogenous peptides simultaneously. 
It is worth noting that our previous work has provided evidence of significant sample loss 
when the amount of peptides were below micrograms using MWCO, and it also 
illustrated a solution to minimize the peptide loss and obtain an optimal peptide 
recovery.36 Specifically, MeOH and NaCl were added to wash the MWCO membrane, 
which is usually comprised of regenerated cellulose, before separation. Numerous free 
hydroxyl groups of cellulose could potentially cause significant non-specific adsorption 
of endogenous peptides when separated by MWCO. The addition of MeOH and NaCl 
may disrupt the interaction and non-specific interactions between peptides and hydroxyl 
groups of the regenerated cellulose. This application has greatly facilitated our 
peptidomic studies of human body fluids and significantly increased the number of 
peptide identification.  
 Peptide identification from tandem MS data is a fundamental task in peptidomic studies. 
The sensitivity and accuracy greatly impacts the performance of peptide identification as 
well as downstream analysis. De novo sequencing and database searching are two of the 
most pivotal cornerstones in both proteomic and peptidomic research by MS. In this 
study, we have improved these two aspects and significantly increased the number of 
endogenous peptides identified expanding the peptidome of CSF. Our study has greatly 
surpassed the previously reported 563 peptides in the CSF peptidome by an extensive and 
combined strategy.38 Specifically, our in house-constructed database was computed based 
on in silico peptide cleavage principles37 of protein precursors and compiled of previous 
reported bioactive endogenous peptides of human. The rationale is functional peptides are 
produced from their precursor proteins by various processing enzymes through different 
pathways.  Cysteine and subtilisin-like protease are involved in two major peptide 
processing pathways and they mainly cleave at the dibasic sites.39, 40 This database 
construction method was described in detail by a previous study.37  With the exclusion of 
non-bioactive peptide precursors, potential novel neuropeptides could be identified more 
specifically and with improved sensitivity.41 De novo sequencing was mostly used when 
a protein database was unavailable and require spectra with higher mass accuracy. The 
Orbitrap mass spectrometer enables both high mass accuracy and increased speed of 
analysis for proteomics and peptidomics analysis. PEAKS DB was performed for de novo 
sequencing to assist in database searching due to its superior performance at sensitivity 
and accuracy.42 In addition, PEAKS provided a more robust result validation and 
precision in controlling the FDR. A total of 645 endogenous peptides (Supplementary 
Table 1) were identified with the improved algorithm described above. Proteome 
Discoverer 1.4 (Thermo Scientific) was also used to search the same raw data file using 
the identical database and searching parameters, but only 53 peptides were identified 
among all the samples. The 645 endogenous peptides identified by Peaks Studio 7 were 
derived from 93 protein precursors. 391 confident identifications were discovered in 
cognitively healthy individuals, while 261 and 208 were found in MCI and AD patients, 
respectively, as illustrated by the Venn Diagrams (Figure 2c).  The 645 unique peptides 
covered a wide variety of biological processes (shown in Figure 2d), molecular functions 
and pathways analyzed by PANTHER gene ontology database search. The top biological 
functional categories include cellular process (24.8%), biological regulation (13.5%), 
metabolic process (13.5%) and organismal process (12.8%). Secretory proteins 
comprised a large portion of the 93 protein precursors and their functions include binding 
(45.1%), catalytic activity (19.7%) and receptor activity (16.9%). The peptides consisted 
of several major neuropeptides families: proSAAS, neurosecretory protein VGF, 
Cholecystokinin (CCK), neuroendocrine protein 7B2, proenkephalin-A, neuroendocrine 
convertase 1, chromogranin-A, prepronociceptin, neurexophilin-3, neuropeptide Y, 
secretogranin1, 2, 3, tachykinin-3, proopiomelanocortin, insulin-like growth factor-1, 
chromogranin-A, orexigenic neuropeptide QRFP, preprotachykinin B etc.  
 
ProSAAS and AD 
ProSAAS, a secretory protein, is expressed in neurons throughout the CNS.43, 44 It is 
proteolytically processed within the regulated secretory pathway and function as a potent 
and specific inhibitor of prohormone convertase 1/3 (PC1/3).45, 46 It is also expressed in 
many non-PC1/3 cells, and therefore, many potential functions are still being unknown.43, 
47 Recently, proSAAS-derived peptides have drawn more and more attention and various 
studies have shown that they are involved in a significant number of physiologically 
behaviors, such as circadian rhythm,48, 49 food intake,50 energy balance and fetal 
neuropeptide processing.44 Intriguingly, proSAAS has been mentioned repeatedly in a 
number of neurodegenerative diseases. ProSAAS immunoreactivity has been observed in 
neuritic plagues and neurofibrillary tangles in patients with Pick’s disease, parkinsonism-
dementia complex and AD.51, 52 Specifically, the N-terminal of proSAAS was found to be 
co-localized with tau inclusions. Moreover, several proteomic studies have discovered 
reduced amount of proSAAS-derived peptides in AD and frontotemporal dementia, 
suggesting it being a potential biomarker.53, 54 More interestingly, a novel anti-aggregant 
chaperone function of proSAAS was reported recently and this anti-aggregation function 
of Aβ42 could be achieved sufficiently from residues 97-180.55  
 
In our study, forty two proSAAS-derived peptides were discovered in human CSF with 
peptide confidence level -10 logP score  15 by PEAKS DB, shown in Table 2. 
Intriguingly, all the observed peptides were either from N-terminus (SAAS42-80) and/or C-
terminus (SAAS207-242, SAAS245-260). It is worth pointing out that the intact forms of big 
LEN (SAAS245-260) and little LEN (SAAS245-254) were discovered, and their sequences are 
LETPAPQVPARRLLPP and LETPAPQVPA respectively. Various fragments of big 
SAAS (SAAS34-59), little SAAS (SAAS42-59), big PEN-LEN (SAAS221-260), PEN 
(SAAS221-242) and Big LEN (SAAS245-260) were also identified. Figure 3a presents a 
representative example of MS/MS spectra of an identified fragment of PEN (SAAS222-238), 
DHDVGSELPPEGVLGA (m/z 796.3882), with a -10 logP score of 51.23. Similar with a 
tryptic peptide shown in Figure 3b, the endogenous peptide was identified with high 
confidence. The label free quantification using peak area was also performed on all the 
discovered endogenous peptides by Peaks Studio and Proteome Discoverer 1.4, but due 
to Peaks Studio not displaying any statistical functions nor the peak area for individual 
peptides of every single raw data file, the peptide quantification results should be 
discussed conservatively and cautiously. More than 80% of the discovered proSAAS-
derived peptides showed a decrease in the MCI and AD groups compared with conntrols 
by Peaks Studio. More commonly, a decreasing trend of peak area was observed from 
healthy controls to MCI to AD. Using Proteome Discoverer two proSAAS-derived 
peptides were confidently identified and matched our criteria to be quantified, which was 
when a peptide was present in at least three out of four individuals’ CSF within each 
group.  Two peptides, DHDVGSELPPEGVLGA and DHDVGSELPPEGVLG, were 
present in all twelve participants and the peak area was highly abundant and was 
quantified by Proteome Discoverer. For peptide DHDVGSELPPEGVLGA, the mean 
peak areas among healthy control, MCI and AD were 4.37E+08, 1.73E+08 and 1.41E+08, 
respectively, and the P value was 0.0206. Furthermore, Tukey’s test suggested the 
concentration decrease of this peptide was significant in MCI (P < 0.05) and AD (P < 
0.05), however the decrease in AD compared to MCI was insignificant. For peptide 
DHDVGSELPPEGVLG, the mean peak area among healthy control, MCI and AD were 
1.87E+08, 7.16E+07 and 4.96E+07 respectively, and the P value was 0.0297. Tukey’s 
test indicated the concentration decrease of this peptide was significant in AD (P < 0.05) 
compared to control, however the decrease in MCI was not statistically significant. 
 Glycoprotein identification and quantification  
For glycoprotein identification and quantification, Proteome Discoverer 1.4 was used 
exclusively. To broaden the identification of low abundant proteins in CSF, proteins with 
one or more unique peptides were considered with a false discovery rate of 0.05 at both 
the peptide and protein level. Proteins with only one unique peptide were manually 
examined by checking the peptide XCorr score and the alignment of amino acids. Each 
sample was subjected to technical triplicates and only proteins identified in at least two 
technical replicates were considered as a confident match. With the database searching 
algorithm and criteria discussed above, as shown in the Venn Diagram of Figure 2a, 502, 
457 and 386 proteins were identified with high confidence, totaling 795 unique proteins 
among all 12 samples (Supplementary Table 2). The 795 proteins identified cover a wide 
variety of biological processes (shown in Figure 2b), molecular functions and pathways 
analyzed by the PANTHER gene ontology database search. The top biological functional 
categories include cellular process (23%), metabolic process (20%), development process 
(12%), and response to stimulus (10%). Secretory proteins comprised a large portion of 
all identified proteins and their functions include binding (28.3%), catalytic activity (28%) 
and receptor activity (17.5%) etc. Figure 3b displays a representative example of an 
MS/MS spectrum of a tryptic peptide of transthyretin 
YTIAALLSPYSYSTTAVVTNPKE (m/z 1245.1498).  
 
Label free quantitation using AUC was used to provide relative quantitation among 
control, MCI and AD glycoproteins. Peak area for each protein was summed and 
normalized by its assigned tryptic peptides. Only peptide precursors with mass accuracy 
≤4 ppm were subjected to extraction of their ion chromatograms. To avoid repeated use 
of a peptide for peak area of several proteins only unique peptides were calculated and 
summed to achieve a more accurate analysis. In order to be quantified and analyzed by 
ANOVA, proteins had to have been present in at least three out of four individuals’ CSF 
within each group. Two example proteins were neural cell adhesion molecule L1 
(L1CAM_HUMAN) and receptor-type tyrosine-protein phosphatase eta 
(PTPRJ_HUAMN) that were only discovered in cognitively healthy individuals.  
L1CAM was present in all four participants in the control group but was not detected in 
either the MCI or AD group. PTPRJ was identified in three out of four participants in the 
control group but none of the MCI or AD groups. Thirteen other proteins displayed 
significant changes (P < 0.05) via one way ANOVA analysis to compare the mean value 
of the peak area among these three groups. The differentially expressed proteins are 
shown in Figure 4 and the proteins were transthyretin (TTHY_HUMAN), apolipoprotein 
E (APOE_HUMAN), contactin-1 (CNTN1_HUMAN), alpha-2-HS-glycoprotein 
(FETUA_HUMAN), histidine-rich glycoprotein (HRG_HUMAN), leucine-rich alpha-2-
glycoprotein (A2GL_HUMAN), cell surface glycoprotein MUC18 (MUC18_HUMAN), 
cell adhesion molecule 2 (CADM2_HUMAN), neuronal cell adhesion molecule 
(NRCAM_HUMAN), neural cell adhesion molecule L1-like protein (CHL1_HUMAN), 
neuronal pentraxin-1 (NPTX1_HUMAN), neuronal growth regulator 1 
(NEGR1_HUMAN), and Dickkopf-related protein 3 (DKK3_HUMAN).  
 Protein Networks   
The Mean peak area, one way ANOVA P value, post-hoc comparisons via Tukey’s HSD 
test of the remaining differentially expressed proteins are shown in Table 3. Figure 5a 
illustrates the protein-protein interaction analysis generated by the database and web-tool 
STRING 10.0 (http://string-db.org/). The total fifteen significantly dysregulated proteins 
were subjected to this molecular interaction tool with parameters: (a) medium confidence 
(default); (b) no more than 10 interactors to show. Two functional modules formed 
tightly connected clusters in the network. Further molecular function analysis identified 
five categories: (1) Receptor activity (40%); (2) Catalytic activity (30%); (3) Binding 
capacity (10%); (4) Enzyme activity (10%); (5) Transporter activity (10%).  
 
Transthyretin and AD 
Intriguingly, transthyretin (TTR) was found to increase 2.42 times (P < 0.05) in MCI and 
decrease to 0.53 times in AD (P < 0.01) compared with controls (Table 3).  The mean 
peak area in healthy control, ACI and AD were 5.55E+08, 1.34E+09, 2.96E+08 
respectively, with one way ANOVA P value 0.0074. TTR is a thyroid hormone carrier 
and plasma retinol transporter. It is encoded by a single gene copy on chromosome 18 in 
humans and is expressed in liver, kidney, pancreas, retinal epithelium, leptomeningeal 
epithelium, choroid plexus and potentially in neurons, which is most importantly related 
to AD.56 Anti-TTR antibodies present in brain parenchyma indicate the neuronal 
endocytosis of TTR from choroid plexus is active and TTR mRNA is effectively 
translated.57, 58 Human studies have shown that TTR co-localized in amyloid plaques and 
vessels in hippocampi of AD patients.57, 58 In addition, anti-TTR serum stained the 
majority of neuronal bodies in AD brains while only 10% of the neurons were stained in 
age-matched cognitively healthy individuals.59 A large number of studies have reported a 
decreased level of TTR in AD patients consistent with our results.60, 61, 62 However, there 
is some inconsistency in the literature on TTR levels being increased in AD patients 
compared to controls in CSF proteomic studies.10, 63  Nevertheless, other CSF proteomics 
studies found a decrease of TTR in AD patients.64, 65, 66 The significance of the increased 
level of TTR in MCI and the decreased level of TTR in AD is not clear, but one potential 
hypothesis is that the increased level in MCI represents a microglial or neuronal reaction 
to early amyloid deposition, which then fails in later stages of AD, represented by the AD 
dementia patients in our study. Moreover, CSF TTR concentration may be determined 
partially by neuronal TTR synthesis, and the reduction in TTR could be explained by 
neuronal loss in AD.59 An alternative hypothesis is that AD patients may have a genetic 
disposition or acquired low CSF TTR level independent of Aβ binding which could 
potentially put them at greater risk of developing plaque pathology, since TTR is an 
established A-carrying protein.56 The discovery that TTR bound Aβ and inhibited fibril 
tangle formation was proved both in vitro and in vivo as discussed below.  
 
The first in vitro observation was made in C. elegans, where a phenotype of defective 
locomotion in Aβ-expressing worms were rescued by wild type human TTR expressed in 
muscle cells.67 In addition, the transgenic AD mouse model Tg2576 showed up-
regulation of TTR in the hippocampus and cerebral cortex and TTR immunoreactivity 
was observed as co-localized with Aβ.68,69 Furthermore, increased Aβ deposition was 
seen in one ventricle that was injected with anti-TTR antibodies.58 In another AD mouse 
model APP23, TTR and Aβ co-staining in the hippocampi, cortical regions and blood 
vessels were also observed.70 The over-expression of wild type human TTR in the mouse 
strain (APP23/hTTR+) corrected the cognitive function and special learning as well as the 
diminished neuropathological changes and amount of Aβ deposition. In vitro studies 
reported that most recombinant TTR variants bound to Aβ and inhibited Aβ 
aggregation.71 Wild type human TTR binds to all forms of soluble Aβ, monomer, 
oligomer and fibrils, but has better affinity with Aβ aggregates than the monomer, and 
Aβ1-42 having higher affinity for binding than Aβ1-40.70, 72, 73 By mass spectrometry 
interaction analysis, it was reported that the human TTR monomer bound Aβ with higher 
affinity than its tetramer form; the binding occurd at the inner β-sheet and EF helix of the 
A strand of TTR.74 Lastly, various groups have reported that TTR interrupted Aβ 
aggregation in vivo.75, 70, 72, 73  
 
More intriguingly, this interaction between TTR and Aβ was found to be mutual, more 
specifically, Aβ was found to dynamically regulate the expression of TTR as discussed 
below. The hippocampal slices of Tg2576 AD mice discussed above had more TTR 
mRNA and protein compared to wild type mice. The same phenomenon was found in the 
cortex and hippocampus of APP23 mice.70, 58, 68 It was assumed that this up-regulation of 
TTR also occurred in human brains since TTR was extensively stained in neurons of AD 
patients whereas there was minimal detectable neuronal staining in age-matched 
cognitively normal controls.59 In addition, the TRR gene has been indicated to be a 
specific downstream target of soluble amyloid precursor protein beta(sAPPβ).76 Thus, the 
quantitative result of TTR in this study could be better supported with these studies. 
During the early stages of AD such as preclinical AD or MCI, TTR is most likely 
sequesters and inhibits Aβ aggregation, and facilitated Aβ clearance. Simultaneously, the 
TTR gene is triggered for upregulation in response to the over-production of Aβ peptides 
and APP. This hypothesis explains why TTR was upregulated in MCI.  Over time, the 
mount of pathogenic Aβ production exceeds the neuronal capacity to neutralize and 
remove them by TTR and other major Aβ binding proteins (ApoE and ApoJ) as disease 
progressed. The neuronal homeostasis network of the Aβ neutralizing capacity is finally 
disrupted and unable to control the disease. The negative feedback between Aβ and TTR 
was dysregulated and new TTR was not expressed due to Aβ over-production. 
Alternatively, neuronal TTR was consumed by Aβ which can cause a decline of TTR in 
advanced AD and neuronal loss in advanced AD led to reduced production of TTR. It 
was inferred that TTR was part of the conventional protein homeostasis network in the 
brain of AD, which includes unfolded protein response, heat shock induced chaperones 
and their co-chaperones, the proteasome ubiquitin system and autophagic responses.56  
   
CONCLUSION  
In conclusion, with an optimized sub-microgram peptide separation method using 
MWCO and in house-constructed bioactive peptide-specific database 645 endogenous 
peptides in CSF were identified. Interestingly, 42 proSAAS peptides discovered were 
exclusively cleaved either from the N- or C-terminal of the proSAAS protein precursor, 
which represents similar sequences as the bioactive peptides big/little SAAS, PEN and 
LEN. Among them, the intact form of big LEN and little LEN were identified, which 
indicates potential bioactivity. Glycoproteins were enriched via lectin affinity 
chromatography, digested, identified by Proteome Discoverer, and quantified by 
comparing area under curve between cognitively healthy, MCI and AD individuals. One 
way ANOVA was applied for statistical analysis, and 15 proteins were found to be 
differentially expressed among the three groups. The dynamic changes of transthyretin 
increasing in MCI and then declining in AD were reported for the first time.     
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Table 1. Characteristics of Study Participants 
Characteristic Control MCI 
    
Age, mean (SD) 74.0(3.1) 76.0(2.9) 75.7(4
Education, mean (SD) 17.0(2) 16.3(3.1) 16.0(2
MMSE score, mean (SD)  29.5(0.6) 28.8(0.9) 20.3(2
Women, No. (%) 3 (75) 2 (50) 2 (50)
APOE4 positive,  
No. (%) 
2 (50) 3 (75) 3 (75)
    
Family history of 
dementia, No. (%) 
0 (0) 2 (50) 1 (25)
Abbreviations:  MMSE, Mini-Mental State Examination; AD, Alzheimer’s disease; MCI, mild cognitive imp
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Table 2 ProSAAS peptides identified in CSF  
Peptide   -10logP      Mass     PPM       m/z RT PTM 
DHDVGSELPPEGVLGA 51.23 1590.753 5.8 796.3882 35.2  
DHDVGSELPPEGVLG 46.48 1519.716 -1.1 760.8641 33.67 
HDVGSELPPEGVLGA                   44.42   1475.7256       -0.9    738.8694 33.56 
 DHDVGSELPPEGVL                      41.55         1462.694         -2.4            732.3525         36.4
8 
SPPLAETGAPR                           40.13   1094.572 -0.5     548.293 19.
56 
SPPLAETG                           38.93   770.381 -1.6     771.387 18.1 
 
AADHDVGSELPPEGVLGA           38.49   1732.8268 -1.4     867.4194 34.41 
DHDVGSELPPEG             37.35   1250.5415 -1.1     626.2773 22.56 
HDVGSELPPEGVLG             37.08   1404.6885 -2     703.3501 32.33 
HDVGSELPPEGVL             35.62   1347.667 -1     674.8401 33.62 
ADHDVGSELPPEGVLGA             35.46   1661.7897 -1     831.9013 34.05 
TPAPQVPARRLLPP             34.97   1511.8936 -1.2     504.9712 30.02 
GLSAASPPLAETGAPR             34.92   1493.7837  0.7     747.8997 27.91 
VGSELPPEGVLGA             34.78   1223.6398  0.3     612.8273 34.71 
HDVGSELPPEG                           34.38   1135.5145  1.6     568.7654 21.13 
DHDVGSELPPEGVLGAL             31.99   1703.8365 -0.5     852.9251 43.02 
DVGSELPPEGVLGA             31.33   1338.6666 -0.7     670.3401 37.44 
SAASPPLAETGAPR             30.54   1323.6782  1.5     662.8474 21.46 
SAASPPLAETGAPRRF             28.46   1626.8478 -0.8     543.2894 26.92 
AADHDVGSELPPEGVLG             27.04   1661.7897  1.5     831.9034 33.21 
ETPAPQVPARR                           26.73   1220.6625 -1.2     407.8943 16.7 
SPPLAETGAPRRF             26.58   1397.7415 -0.6    466.9208 25.54 
ETPAPQVPARRLLPP             26.44   1640.9362  1.4    547.9868 31.03 
DVGSELPPEG                           26.23    998.4556 -1.4    500.2344 25.02 
DVGSELPPEGVL                           24.73   1210.608  0.2    606.3114 37.9 
DVGSELPPEGVLG             24.32   1267.6295  1.7    634.8231 36.66 
ADHDVGSELPPEGVLG             24.27   1590.7526 -3.3    796.3809 33.38 
DHDVGSELPPEGVL                      23.95   1461.71 -1.3    731.8613 33.14   
amidation 
LSAASPPLAETGAPRRF             21.23   1739.9318 -0.3    580.9844 29.46 
DHDVGSELPPEGVLGALL             21.18   1816.9207  1.1    909.4686 49.79 
DHDVGSELPPEGVLGALLRV        21   2072.0901 -0.5    691.7036 51.84 
ADSEGVAAPRRLRRAADHDV-    20.34   2926.4756 -8.6    976.4908         30.44   
amidation 
-GSELPPEG  
LPPEG                                           19.5    511.2642 -2.1    512.2704 14.01 
PPEGVLGAL                            19.14    851.4752 -0.2    426.7448 31.34 
ETPAPQVPA                            18    908.4603 -1.4    455.2368 22.48 
F(+42.01)RRSVP                           17.92    802.4449 -3.8    402.2282 22.43   acetylation 
SVPRGEAAGAVQELARA             17.31   1680.8906  1.6    561.3051 30.01 
LETPAPQVPARRLLPP             16.26   1754.0203  0    585.6807 32.7 
LSAASPPLAETGAPR             16.22   1436.7623 -3.4    719.386 25.52 
LAETGAPR                            15.75    813.4344 -4.7    407.7226 14.34 
DHDVGSELPPEGV             15.13   1349.6099 -4.2    675.8094 27.96 
LETPAPQVPA                            15.11   1021.5444  0    511.7795 26.94 
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Table 3. Proteins showed differential expression in CSF among healthy control, MCI and 
AD 
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Figure Caption  
Figure 1 Schematic illustration of the experimental design. 
Figure 2 Number of proteins and endogenous peptides identified and their biological 
functions. (a) Venn Diagram displaying 502, 457 and 386 proteins identified with high 
confidence in control, MCI and AD participants biological process. (b) Biological 
process of total identified 795 proteins by PANTHER gene ontology search. (c) Venn 
Diagram showing 391, 261 and 208 endogenous peptides found in control, MCI and AD 
individuals. (d) Biological process of total identified 93 protein precursors by PANTHER 
gene ontology search. 
Figure 3 Tandem mass spectra of representative endogenous peptides and tryptic 
peptides (a) Endogenous peptide DHDVGSELPPEGVLGA derived from proSAAS 
protein precursor (b) Tryptic peptide of transthyretin YTIAALLSPYSYSTTAVVTNPKE  
Figure 4 One way ANOVA analysis results of differentially altered glycoproteins via bar 
chart. (a) leucine-rich alpha-2-glycoprotein (b) cell surface glycoprotein MUC18 (c) 
neural cell adhesion molecule L1-like protein (d) cell adhesion molecule 2 (e) histidine-
rich glycoprotein (f) neuronal cell adhesion molecule (g) neuronal pentraxin-1 (h) 
neuronal growth regulator 1 (i) Dickkopf-related protein 3 (j) apolipoprotein E (k) 
transthyretin (l) alpha-2-HS-glycoprotein (M) contactin-1 
Figure 5 (a) Protein-protein interaction analysis of fifteen significantly altered 
glycoproteins by STRING 10.0. (b) Molecular functions of significantly changed 
glycoproteins by PANTHER gene ontology search. 
